OTC · CSLLY
Healthcare · Biotechnology
$30.93
Down-$0.74 (-2.32%)
Updated Sep 16, 2026, 5:08 PM
SID Score
6.3/10
Composite research score
Smart Money
46/100
Neutral
Price performance
1M range · 0 trading sessions · Daily adjusted prices
CSLLY does not have enough price history for the selected period.
Data unavailable
The requested market data was not found.
The latest Smart Investors Daily articles mentioning CSLLY.
CSLLY research
Company profile and research snapshot.
CSL LTD SP/ADR
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 1, 2026 | BELL POTTER SECURITIES | Hold | — |
| Jun 29, 2026 | MACQUARIE RESEARCH | Neutral | — |
| Jun 24, 2026 | JEFFERIES | Hold | — |
| May 12, 2026 | JEFFERIES | Buy | — |
| May 11, 2026 | CANACCORD GENUITY | Hold | — |
No generated briefing is available yet.
Yahoo · Sep 10, 2026
CSL Seqirus, a business of CSL (ASX: CSL; USOTC: CSLLY), today announced publication of pivotal Phase 3 study results for its MF59®-adjuvanted cell-based higher-dose quadrivalent influenza vaccine (aQIVc) in The Lancet Infectious Diseases, marking an important milestone in the evolution of influenza prevention for older adults.1
Yahoo · Sep 10, 2026
This article first appeared on GuruFocus. CSL Ltd (CSLLY) recently announced a total dividend of $0.41 per share, with the ex-dividend date set for 2026-09-10. This includes a $0.41 per share cash dividend payable on 2026-10-09.
SeekingAlpha · Aug 18, 2026
CSL Limited (CSLLY) Q4 2026 Earnings Call August 17, 2026 8:01 PM EDTCompany ParticipantsMichelle ReesGordon Naylor - CEO, MD & DirectorKen Lim - Chief...
SeekingAlpha · Aug 17, 2026
2026-08-17. The following slide deck was published by CSL Limited in conjunction with their 2026 Q4 earnings call.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning CSLLY.
